CD274 and non-small cell lung carcinoma: In untreated advanced NSCLC, first-line with PD-L1 expression ≥ 50% and no genetic mutation, pembrolizumab achieved significantly better OS compared to the chemotherapy group in the KEYNOTE-024 trial.